rs140379348
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_002691.4(POLD1):c.1517G>A(p.Arg506His) variant causes a missense change. The variant allele was found at a frequency of 0.0000191 in 1,415,524 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.000021 ( 0 hom., cov: 30)
Exomes 𝑓: 0.000019 ( 0 hom. )
Consequence
POLD1
NM_002691.4 missense
NM_002691.4 missense
Scores
5
6
8
Clinical Significance
Conservation
PhyloP100: 6.05
Genes affected
POLD1 (HGNC:9175): (DNA polymerase delta 1, catalytic subunit) This gene encodes the 125-kDa catalytic subunit of DNA polymerase delta. DNA polymerase delta possesses both polymerase and 3' to 5' exonuclease activity and plays a critical role in DNA replication and repair. Alternatively spliced transcript variants have been observed for this gene, and a pseudogene of this gene is located on the long arm of chromosome 6. [provided by RefSeq, Mar 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
BS2
High AC in GnomAdExome4 at 24 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POLD1 | NM_002691.4 | c.1517G>A | p.Arg506His | missense_variant | 13/27 | ENST00000440232.7 | NP_002682.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POLD1 | ENST00000440232.7 | c.1517G>A | p.Arg506His | missense_variant | 13/27 | 1 | NM_002691.4 | ENSP00000406046 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000208 AC: 3AN: 144186Hom.: 0 Cov.: 30
GnomAD3 genomes
AF:
AC:
3
AN:
144186
Hom.:
Cov.:
30
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000815 AC: 2AN: 245380Hom.: 0 AF XY: 0.00000752 AC XY: 1AN XY: 132906
GnomAD3 exomes
AF:
AC:
2
AN:
245380
Hom.:
AF XY:
AC XY:
1
AN XY:
132906
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000189 AC: 24AN: 1271338Hom.: 0 Cov.: 34 AF XY: 0.0000159 AC XY: 10AN XY: 630384
GnomAD4 exome
AF:
AC:
24
AN:
1271338
Hom.:
Cov.:
34
AF XY:
AC XY:
10
AN XY:
630384
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000208 AC: 3AN: 144186Hom.: 0 Cov.: 30 AF XY: 0.0000143 AC XY: 1AN XY: 70080
GnomAD4 genome
AF:
AC:
3
AN:
144186
Hom.:
Cov.:
30
AF XY:
AC XY:
1
AN XY:
70080
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
1
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jul 04, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 20, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in an individual with low grade glioma in published literature (PMID: 26580448); Published functional studies support no damaging effect: no effect on cell growth, sensitivity to DNA-damaging agents, protein abundance, or POLD1 mismatch repair activity, but slightly reduced DNA replication fidelity (PMID: 19966286, 34530183); This variant is associated with the following publications: (PMID: 21157497, 10074927, 27320729, 28368425, 7704014, 28687338, 33144657, 35620275, 34530183, 19966286, 26580448, 20951805) - |
Colorectal cancer, susceptibility to, 10 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 506 of the POLD1 protein (p.Arg506His). This variant is present in population databases (rs140379348, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with POLD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 239242). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POLD1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects POLD1 function (PMID: 19966286). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Oct 08, 2023 | - - |
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Aug 13, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 12, 2022 | The p.R506H variant (also known as c.1517G>A), located in coding exon 12 of the POLD1 gene, results from a G to A substitution at nucleotide position 1517. The arginine at codon 506 is replaced by histidine, an amino acid with highly similar properties. In one yeast-based assay, this variant showed slightly reduced fidelity of DNA replication, which was compensated for by functional mismatch repair in wild type cells (Daee DL et al. Proc. Natl. Acad. Sci. U.S.A., 2010 Jan;107:157-62). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
POLD1-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 18, 2023 | The POLD1 c.1517G>A variant is predicted to result in the amino acid substitution p.Arg506His. This variant was previously identified in human colorectal adenocarcinoma cell lines defective in MMR, and showed reduced DNA proofreading activity, but also occurred with other causative variants (da Costa et al. 1995. PubMed ID: 7704014; Table 1, Yoshida et al. 2011. PubMed ID: 21157497; Prindle and Loeb. 2012. PubMed ID: 23065663; Nicolas et al. 2016. PubMed ID: 27320729). This variant is reported in 0.0051% of alleles in individuals of East Asian descent in gnomAD and is reported in ClinVar as a variant of uncertain significance (https://www.ncbi.nlm.nih.gov/clinvar/variation/239242/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Dec 28, 2016 | The p.Arg506His variant in POLD1 has not been previously reported in individuals with colorectal cancer, but has been identified in 1/64598 of European chromoso mes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; d bSNP rs140379348). In vitro functional studies provide some evidence that the p. Arg506His variant may impact protein function (Daee 2010). However, these types of assays may not accurately represent biological function. Computational predic tion tools and conservation analysis do not provide strong support for or agains t an impact to the protein. In summary, the clinical significance of the p.Arg50 6His variant is uncertain. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;.;.;D
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
.;.;D;D
M_CAP
Benign
D
MetaRNN
Uncertain
D;D;D;D
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;.;.;M
MutationTaster
Benign
D
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D;.;.;.
REVEL
Benign
Sift
Benign
T;.;.;.
Sift4G
Benign
T;T;T;T
Polyphen
P;.;.;P
Vest4
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at